News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Prices $7.5 million Public Offering

February 7, 2020 • 8:45 AM EST

Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD

February 5, 2020 • 5:15 PM EST

Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences

February 4, 2020 • 7:00 AM EST

Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference

January 29, 2020 • 4:15 PM EST

Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL

January 24, 2020 • 7:00 AM EST

Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference

January 23, 2020 • 7:00 AM EST

Tonix Pharmaceuticals to Present at Biotech Showcase 2020

January 7, 2020 • 7:00 AM EST

Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study

December 16, 2019 • 3:15 PM EST

Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL

December 11, 2019 • 4:05 PM EST

Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

December 10, 2019 • 7:00 AM EST

« Previous
1...
5
6
7
8
9
10
11
12
13
14
...41
Next »

Show All